Strategies for overcoming the biological barriers associated with the administration of inhaled monoclonal antibodies for lung diseases

References

• Rogliani P, Calzetta L, Matera MG, et al. Severe asthma and biological therapy: when, which, and for whom. Pulm Ther. 2020;6(1):47–66. doi: 10.1007/s41030-019-00109-1
   PubMedGoogle Scholar
• Matera MG, Calzetta L, Cazzola M, et al. Biologic therapies for chronic obstructive pulmonary disease. Expert Opin Biol Ther. 2023;23(2):163–173. doi: 10.1080/14712598.2022.2160238
   PubMed Web of Science ®Google Scholar
• Esposito S, Amirthalingam G, Bassetti M, et al. Monoclonal antibodies for prophylaxis and therapy of respiratory syncytial virus, SARS-CoV-2, human immunodeficiency virus, rabies and bacterial infections: an update from the world association of infectious diseases and immunological disorders and the Italian society of antinfective therapy. Front Immunol. 2023;14:1162342.
   PubMed Web of Science ®Google Scholar
• Tamimi A, Tamimi A, Sorkheh F, et al. Monoclonal antibodies for the treatment of squamous cell carcinoma: a literature review. Cancer Rep (Hoboken). 2023;6(5):e1802. doi: 10.1002/cnr2.1802
   PubMedGoogle Scholar
• Rocco D, Della Gravara L, Battiloro C, et al. Recently approved and emerging monoclonal antibody immune checkpoint inhibitors for treating advanced non-small cell lung cancer. Expert Opin Biol Ther. 2023;23(3):261–268. doi: 10.1080/14712598.2023.2183116
   PubMed Web of Science ®Google Scholar
• Matera MG, Calzetta L, Rogliani P, et al. Monoclonal antibodies for severe asthma: pharmacokinetic profiles. Respir med. 2019;153:3–13. doi: 10.1016/j.rmed.2019.05.005
   PubMed Web of Science ®Google Scholar
• Cruz-Teran C, Tiruthani K, McSweeney M, et al. Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy. Adv Drug Deliv Rev. 2021;169:100–117. doi: 10.1016/j.addr.2020.12.004
   PubMed Web of Science ®Google Scholar
• Hansel TT, Kropshofer H, Singer T, et al. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov. 2010;9(4):325–338. doi: 10.1038/nrd3003
   PubMed Web of Science ®Google Scholar
• Maillet A, Guilleminault L, Lemarié E, et al. The airways, a novel route for delivering monoclonal antibodies to treat lung tumors. Pharm Res. 2011;28(9):2147–2156. doi: 10.1007/s11095-011-0442-5
   PubMed Web of Science ®Google Scholar
• Guilleminault L, Azzopardi N, Arnoult C, et al. Fate of inhaled monoclonal antibodies after the deposition of aerosolized particles in the respiratory system. J Control Release. 2014;196:344–354. doi: 10.1016/j.jconrel.2014.10.003
   PubMed Web of Science ®Google Scholar
• Tomkinson A, Tepper J, Morton M, et al. Inhaled vs subcutaneous effects of a dual IL-4/IL-13 antagonist in a monkey model of asthma. Allergy. 2010;65(1):69–77. doi: 10.1111/j.1398-9995.2009.02156.x
   PubMed Web of Science ®Google Scholar
• Borghardt JM, Kloft C, Sharma A. Inhaled therapy in respiratory disease: the complex interplay of pulmonary kinetic processes. Can Respir J. 2018;2018:2732017. doi: 10.1155/2018/2732017
   PubMed Web of Science ®Google Scholar
• Desoubeaux G, Reichert JM, Sleeman M, et al. Therapeutic monoclonal antibodies for respiratory diseases: current challenges and perspectives, March 31 - April 1, 2016, tours, France. MAbs. 2016;8(6):999–1009. doi: 10.1080/19420862.2016.1196521
   PubMed Web of Science ®Google Scholar
• Matera MG, Page C, Rogliani P, et al. Therapeutic monoclonal antibodies for the treatment of chronic obstructive pulmonary disease. Drugs. 2016;76(13):1257–1270. doi: 10.1007/s40265-016-0625-9
   PubMed Web of Science ®Google Scholar
• Osman N, Kaneko K, Carini V, et al. Carriers for the targeted delivery of aerosolized macromolecules for pulmonary pathologies. Expert Opin Drug Deliv. 2018;15(8):821–834. doi: 10.1080/17425247.2018.1502267
   PubMed Web of Science ®Google Scholar
• Liang W, Pan HW, Vllasaliu D, et al. Pulmonary delivery of biological drugs. Pharmaceutics. 2020; 12(11):E1025. doi: 10.3390/pharmaceutics12111025
   PubMed Web of Science ®Google Scholar
• Plaunt AJ, Nguyen TL, Corboz MR, et al. Strategies to overcome biological barriers associated with pulmonary drug delivery. Pharmaceutics. 2022; 14(2):302. doi: 10.3390/pharmaceutics14020302
   PubMed Web of Science ®Google Scholar
• Ray A, Mandal A, Mitra AK. Recent patents in pulmonary delivery of macromolecules. Recent Pat Drug Deliv Formul. 2015;9(3):225–236. doi: 10.2174/1872211309666150729122231
   PubMedGoogle Scholar
• Gopallawa I, Dehinwal R, Bhatia V, et al. A four-part guide to lung immunology: invasion, inflammation, immunity, and intervention. Front Immunol. 2023;14:1119564. doi: 10.3389/fimmu.2023.1119564
   PubMed Web of Science ®Google Scholar
• Fehrenbach H. Alveolar epithelial type II cell: defender of the alveolus revisited. Respir Res. 2001;2(1):33–46. doi: 10.1186/rr36
   PubMed Web of Science ®Google Scholar
• Hou F, Xiao K, Tang L, et al. Diversity of macrophages in lung homeostasis and diseases. Front Immunol. 2021;12:753940. doi: 10.3389/fimmu.2021.753940
   PubMed Web of Science ®Google Scholar
• Shi T, Denney L, An H, et al. Alveolar and lung interstitial macrophages: definitions, functions, and roles in lung fibrosis. J Leukocyte Biol. 2021;110(1):107–114. doi: 10.1002/JLB.3RU0720-418R
   PubMed Web of Science ®Google Scholar
• Lombry C, Edwards DA, Préat V, et al. Alveolar macrophages are a primary barrier to pulmonary absorption of macromolecules. Am J Physiol Lung Cell Mol Physiol. 2004;286(5):L1002–L1008. doi: 10.1152/ajplung.00260.2003
   PubMed Web of Science ®Google Scholar
• Sécher T, Mayor A, Heuzé-Vourc’h N. Inhalation of immuno-therapeutics/-prophylactics to fight respiratory tract infections: an appropriate drug at the right place! Front Immunol. 2019;10:2760. doi: 10.3389/fimmu.2019.02760
   PubMed Web of Science ®Google Scholar
• Respaud R, Marchand D, Parent C, et al. Effect of formulation on the stability and aerosol performance of a nebulized antibody. MAbs. 2014;6(5):1347–1355. doi: 10.4161/mabs.29938
   PubMed Web of Science ®Google Scholar
• Newman SP. Drug delivery to the lungs: challenges and opportunities. Ther Deliv. 2017;8(8):647–661. doi: 10.4155/tde-2017-0037
   PubMed Web of Science ®Google Scholar
• Spiekermann GM, Finn PW, Ward ES, et al. Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life: functional expression of FcRn in the mammalian lung. J Exp Med. 2002;196(3):303–310. doi: 10.1084/jem.20020400
   PubMed Web of Science ®Google Scholar
• Bitonti AJ, Dumont JA, Low SC, et al. Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway. Proc Natl Acad Sci U S A. 2004;101(26):9763–9768. doi: 10.1073/pnas.0403235101
   PubMed Web of Science ®Google Scholar
• Patton JS, Brain JD, Davies LA, et al. The particle has landed—characterizing the fate of inhaled pharmaceuticals. J Aerosol Med Pulm Drug Deliv. 2010;23 Suppl 2(S2):S71–S87. doi: 10.1089/jamp.2010.0836
   PubMedGoogle Scholar
• Ruge CA, Kirch J, Lehr CM. Pulmonary drug delivery: from generating aerosols to overcoming biological barriers-therapeutic possibilities and technological challenges. Lancet Respir Med. 2013;1(5):402–413. doi: 10.1016/S2213-2600(13)70072-9
   PubMed Web of Science ®Google Scholar
• Ghadiri M, Young PM, Traini D. Strategies to enhance drug absorption via nasal and pulmonary routes. Pharmaceutics. 2019;11(3):113. doi: 10.3390/pharmaceutics11030113
   PubMed Web of Science ®Google Scholar
• Man F, Tang J, Swedrowska M, et al. Imaging drug delivery to the lungs: methods and applications in oncology. Adv Drug Deliv Rev. 2023;192:114641. doi: 10.1016/j.addr.2022.114641
   PubMed Web of Science ®Google Scholar
• Matthews AA, Ee PLR, Ge R. Developing inhaled protein therapeutics for lung diseases. Mol Biomed. 2020;1(1):11. doi: 10.1186/s43556-020-00014-z
   PubMedGoogle Scholar
• Ferrati S, Wu T, Kanapuram SR, et al. Dosing considerations for inhaled biologics. Int J Pharm. 2018;549(1–2):58–66. doi: 10.1016/j.ijpharm.2018.07.054
   PubMedGoogle Scholar
• Kim KJ, Malik AB. Protein transport across the lung epithelial barrier. Am J Physiol Lung Cell Mol Physiol. 2003;284(2):L247–L259. doi: 10.1152/ajplung.00235.2002
   PubMed Web of Science ®Google Scholar
• Vonarburg C, Loetscher M, Spycher MO, et al. Topical application of nebulized human IgG, IgA and IgAM in the lungs of rats and non-human primates. Respir Res. 2019;20(1):99. doi: 10.1186/s12931-019-1057-3
   PubMedGoogle Scholar
• Ruge CA, Schaefer UF, Herrmann J, et al. The interplay of lung surfactant proteins and lipids assimilates the macrophage clearance of nanoparticles. PLoS One. 2012;7(7):e40775. doi: 10.1371/journal.pone.0040775
   PubMed Web of Science ®Google Scholar
• Patton JS, Fishburn CS, Weers JG. The lungs as a portal of entry for systemic drug delivery. Proc Am Thorac Soc. 2004;1(4):338–344. doi: 10.1513/pats.200409-049TA
   PubMedGoogle Scholar
• Zheng J, Zheng Y, Chen J, et al. Enhanced pulmonary absorption of recombinant human insulin by pulmonary surfactant and phospholipid hexadecanol tyloxapol through calu-3 monolayers. Pharmazie. 2012;67(5):448–451.
   PubMed Web of Science ®Google Scholar
• Zhang R, Qin X, Kong F, et al. Improving cellular uptake of therapeutic entities through interaction with components of cell membrane. Drug Deliv. 2019;26(1):328–342. doi: 10.1080/10717544.2019.1582730
   PubMed Web of Science ®Google Scholar
• Bodier-Montagutelli E, Mayor A, Vecellio L, et al. Designing inhaled protein therapeutics for topical lung delivery: what are the next steps? Expert Opin Drug Deliv. 2018;15(8):729–736. doi: 10.1080/17425247.2018.1503251
   PubMed Web of Science ®Google Scholar
• Siekmeier R, Scheuch G. Systemic treatment by inhalation of macromolecules–principles, problems, and examples. J Physiol Pharmacol. 2008;59(Suppl 6):53–79.
   PubMedGoogle Scholar
• Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol. 2003;56(6):588–599. doi: 10.1046/j.1365-2125.2003.01892.x
   PubMed Web of Science ®Google Scholar
• Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov. 2007;6(1):67–74. doi: 10.1038/nrd2153
   PubMed Web of Science ®Google Scholar
• Andrade F, Videira M, Ferreira D, et al. Nanocarriers for pulmonary administration of peptides and therapeutic proteins. Nanomedicine (Lond). 2011;6(1):123–141. doi: 10.2217/nnm.10.143
   PubMed Web of Science ®Google Scholar
• Fröhlich E, Salar-Behzadi S. Oral inhalation for delivery of proteins and peptides to the lungs. Eur J Pharm Biopharm. 2021;163:198–211.
   PubMed Web of Science ®Google Scholar
• Kastelik JA, Thompson RH, Aziz I, et al. Sex-related differences in cough reflex sensitivity in patients with chronic cough. Am J Respir Crit Care Med. 2002;166(7):961–964. doi: 10.1164/rccm.2109061
   PubMed Web of Science ®Google Scholar
• Geller DE, Nasr SZ, Piggott S, et al. Tobramycin inhalation powder in cystic fibrosis patients: response by age group. Respir Care. 2014;59(3):388–398. doi: 10.4187/respcare.02264
   PubMed Web of Science ®Google Scholar
• Ebihara S, Ebihara T, Kohzuki M. Effect of aging on cough and swallowing reflexes: implications for preventing aspiration pneumonia. Lung. 2012;190(1):29–33. doi: 10.1007/s00408-011-9334-z
   PubMed Web of Science ®Google Scholar
• Respaud R, Vecellio L, Diot P, et al. Nebulization as a delivery method for mAbs in respiratory diseases. Expert Opin Drug Deliv. 2015;12(6):1027–1039. doi: 10.1517/17425247.2015.999039
   PubMed Web of Science ®Google Scholar
• Bodier-Montagutelli E, Respaud R, Perret G, et al. Protein stability during nebulization: mind the collection step! Eur J Pharm Biopharm. 2020;152:23–34. doi: 10.1016/j.ejpb.2020.04.006
   PubMed Web of Science ®Google Scholar
• Narang A, Krause M, Pizzarro S, et al. Biologic drug substance and drug product manufacture. In: Hickey A Rocha S, editors. Pharmaceutical inhalation aerosol technology. Boca Raton (FL): CRC Press; 2019. p. 206–232. doi: 10.1201/9780429055201-8
   Google Scholar
• Niven RW, Prestrelski SJ, Treuheit MJ, et al. Protein nebulization.2. Stabilization of G-CSF to air-jet nebulization and the role of protectants. International Journal Of Pharmaceutics. 1996;127(2):191–201. doi: 10.1016/0378-5173(95)04209-1
   Web of Science ®Google Scholar
• Niven RW, Ip AY, Mittelman SD, et al. Protein nebulization: I. stability of lactate dehydrogenase and recombinant granulocyte-colony stimulating factor to air-jet nebulization. Int J Pharm. 1994;109(1):17–26. doi: 10.1016/0378-5173(94)90117-1
   Google Scholar
• Parray HA, Shukla S, Perween R, et al. Inhalation monoclonal antibody therapy: a new way to treat and manage respiratory infections. Appl Microbiol Biotechnol. 2021;105(16–17):6315–6332. doi: 10.1007/s00253-021-11488-4
   PubMed Web of Science ®Google Scholar
• Pritchard JN, Hatley RH, Denyer J, et al. Mesh nebulizers have become the first choice for new nebulized pharmaceutical drug developments. Ther Deliv. 2018;9(2):121–136. doi: 10.4155/tde-2017-0102
   PubMed Web of Science ®Google Scholar
• Pleasants RA, Hess DR. Aerosol delivery devices for obstructive lung diseases. Respir Care. 2018;63(6):708–733. doi: 10.4187/respcare.06290
   PubMed Web of Science ®Google Scholar
• Arı A. Jet, ultrasonic, and mesh nebulisers: an evaluation of nebulizers for better clinical outcomes. Eurasian J Pulmonol. 2014;16(1):1–7. doi: 10.5152/ejp.2014.00087
   Google Scholar
• Rangaraj N, Pailla SR, Sampathi S. Insight into pulmonary drug delivery: mechanism of drug deposition to device characterization and regulatory requirements. Pulm Pharmacol Ther. 2019;54:1–21. doi: 10.1016/j.pupt.2018.11.004
   PubMed Web of Science ®Google Scholar
• Telko MJ, Hickey AJ. Dry powder inhaler formulation. Respir Care. 2005;50(9):1209–1227.
   PubMedGoogle Scholar
• Vehring R. Pharmaceutical particle engineering via spray drying. Pharm Res. 2008;25(5):999–1022. doi: 10.1007/s11095-007-9475-1
   PubMed Web of Science ®Google Scholar
• Brunaugh AD, Ding L, Wu T, et al. Identification of stability constraints in the particle engineering of an inhaled monoclonal antibody dried powder. J Pharm Sci. 2022;111(2):403–416. doi: 10.1016/j.xphs.2021.08.022
   PubMed Web of Science ®Google Scholar
• Faghihi H, Najafabadi AR, Vatanara A. Optimization and characterization of spray-dried IgG formulations: a design of experiment approach. DARU, J Pharm Sci. 2017;25(1):22. doi: 10.1186/s40199-017-0187-8
   Google Scholar
• Morgan BA, Manser M, Jeyanathan M, et al. Effect of shear stresses on adenovirus activity and aggregation during atomization to produce thermally stable vaccines by spray drying. ACS Biomater Sci Eng. 2020;6(7):4304–4313. doi: 10.1021/acsbiomaterials.0c00317
   PubMed Web of Science ®Google Scholar
• Dao HM, Sahakijpijarn S, Chrostowski RR, et al. Aggregation of lactoferrin caused by droplet atomization process via a two-fluid nozzle: the detrimental effect of air-water interfaces. Mol Pharm. 2022;19(7):2662–2675. doi: 10.1021/acs.molpharmaceut.2c00358
   PubMedGoogle Scholar
• Perodeau J, Arbogast LW, Nieuwkoop AJ. Solid-state NMR characterization of lyophilized formulations of monoclonal antibody therapeutics. Mol Pharm. 2023; 20(3):1480–1489. doi: 10.1021/acs.molpharmaceut.2c00676
   PubMedGoogle Scholar
• Hickey AJ, Stewart IE. Inhaled antibodies: quality and performance considerations. Hum Vaccin Immunother. 2022; 18(2):1940650. doi: 10.1080/21645515.2021.1940650
   PubMed Web of Science ®Google Scholar
• Hickey A. Complexity in pharmaceutical powders for inhalation: a perspective. Kona. 2018;35:3–13. doi: 10.14356/kona.2018007
   Google Scholar
• Chow MYT, Pan HW, Seow HC, et al. Inhalable neutralizing antibodies - promising approach to combating respiratory viral infections. Trends Pharmacol Sci. 2023; 44(2):85–97. doi: 10.1016/j.tips.2022.11.006
   PubMed Web of Science ®Google Scholar
• Fathe K, Ferrati S, Moraga-Espinoza D, et al. Inhaled biologics: from preclinical to product approval. Curr Pharm Des. 2016;22(17):2501–2521. doi: 10.2174/1381612822666160210142910
   PubMed Web of Science ®Google Scholar
• Liao YH, Brown MB, Jones SA, et al. The effects of polyvinyl alcohol on the in vitro stability and delivery of spray-dried protein particles from surfactant-free HFA 134a-based pressurised metered dose inhalers. Int J Pharm. 2005;304(1–2):29–39. doi: 10.1016/j.ijpharm.2005.07.013
   PubMedGoogle Scholar
• Li HY, Seville PC. Novel pMDI formulations for pulmonary delivery of proteins. Int J Pharm. 2010;385(1–2):73–78. doi: 10.1016/j.ijpharm.2009.10.032
   PubMed Web of Science ®Google Scholar
• Wang W, Singh S, Zeng DL, et al. Antibody structure, instability, and formulation. J Pharm Sci. 2007;96(1):1–26. doi: 10.1002/jps.20727
   PubMed Web of Science ®Google Scholar
• Le Basle Y, Chennell P, Tokhadze N, et al. Physicochemical stability of monoclonal antibodies: a review. J Pharm Sci. 2020; 109(1):169–190. doi: 10.1016/j.xphs.2019.08.009
   PubMed Web of Science ®Google Scholar
• Chennamsetty N, Voynov V, Kayser V, et al. Design of therapeutic proteins with enhanced stability. Proc Natl Acad Sci U S A. 2009;106(29):11937–11942. doi: 10.1073/pnas.0904191106
   PubMed Web of Science ®Google Scholar
• Mayor A, Thibert B, Huille S, et al. Inhaled IgG1 antibodies: the buffering system is an important driver of stability during mesh-nebulization. Eur J Pharm Biopharm. 2022;181:173–182. doi: 10.1016/j.ejpb.2022.11.006
   PubMed Web of Science ®Google Scholar
• Deuschle FC, Ilyukhina E, Skerra A. Anticalin® proteins: from bench to bedside. Expert Opin Biol Ther. 2021; 21(4):509–518. doi: 10.1080/14712598.2021.1839046
   PubMed Web of Science ®Google Scholar
• Nelson AL. Antibody fragments: hope and hype. MAbs. 2010;2(1):77–83. doi: 10.4161/mabs.2.1.10786
   PubMed Web of Science ®Google Scholar
• Muyldermans S. Nanobodies: natural single-domain antibodies. Annu Rev Biochem. 2013;82(1):775–797. doi: 10.1146/annurev-biochem-063011-092449
   PubMed Web of Science ®Google Scholar
• Steeland S, Vandenbroucke RE, Libert C. Nanobodies as therapeutics: big opportunities for small antibodies. Drug Discov Today. 2016;21(7):1076–1113. doi: 10.1016/j.drudis.2016.04.003
   PubMed Web of Science ®Google Scholar
• Loira-Pastoriza C, Todoroff J, Vanbever R. Delivery strategies for sustained drug release in the lungs. Adv Drug Deliv Rev. 2014;75:81–91. doi: 10.1016/j.addr.2014.05.017
   PubMed Web of Science ®Google Scholar
• Patil HP, Freches D, Karmani L, et al. Fate of PEGylated antibody fragments following delivery to the lungs: influence of delivery site, PEG size and lung inflammation. J Control Release. 2018;272:62–71. doi: 10.1016/j.jconrel.2017.12.009
   PubMed Web of Science ®Google Scholar
• Matera MG, Calzetta L, Ora J, et al. Pharmacokinetic/Pharmacodynamic approaches to drug delivery design for inhalation drugs. Expert Opin Drug Deliv. 2021;18(7):891–906. doi: 10.1080/17425247.2021.1873271
   PubMed Web of Science ®Google Scholar
• Olsson B, Bondesson E, Borgström L. Pulmonary drug metabolism, clearance, and absorption. In: Smyth H Hickey A editors. Controlled pulmonary drug delivery. (NY): Springer; 2011. p. 21–50. doi: 10.1007/978-1-4419-9745-6_2
   Google Scholar
• Guillon A, Sécher T, Dailey LA, et al. Insights on animal models to investigate inhalation therapy: relevance for biotherapeutics. Int J Pharm. 2018;536(1):116–126. doi: 10.1016/j.ijpharm.2017.11.049
   PubMedGoogle Scholar
• Guillon A, Pardessus J, Lhommet P, et al. Exploring the fate of inhaled monoclonal antibody in the lung parenchyma by microdialysis. MAbs. 2019;11(2):297–304. doi: 10.1080/19420862.2018.1556081
   PubMed Web of Science ®Google Scholar
• Röhm M, Carle S, Maigler F, et al. A comprehensive screening platform for aerosolizable protein formulations for intranasal and pulmonary drug delivery. Int J Pharm. 2017;532(1):537–546. doi: 10.1016/j.ijpharm.2017.09.027
   PubMedGoogle Scholar
• Benam KH, Novak R, Nawroth J, et al. Matched-comparative modeling of normal and diseased human airway responses using a microengineered breathing lung chip. Cell Syst. 2016;3(5):456–466. doi: 10.1016/j.cels.2016.10.003
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Guidance for industry–estimating the maximum safe dose in initial clinical trials for therapeutics in adult healthy volunteers. 2005. http://www.fda.gov/downloads/Drugs/Guidances/UCM078932.pdf
   Google Scholar
• Tibbitts J, Cavagnaro JA, Haller CA, et al. Practical approaches to dose selection for first-in-human clinical trials with novel biopharmaceuticals. Regul Toxicol Pharmacol. 2010;58(2):243–251. doi: 10.1016/j.yrtph.2010.06.007
   PubMed Web of Science ®Google Scholar
• Benam KH, Novak R, Nawroth J, et al. Matched-comparative modeling of normal and diseased human airway responses using a microengineered breathing cung chip. Cell Syst. 2016;3(5):456–466.e4. doi: 10.1016/j.cels.2016.10.003
   PubMed Web of Science ®Google Scholar
• Sengupta A, Dorn A, Jamshidi M, et al. A multiplex inhalation platform to model in situ like aerosol delivery in a breathing lung-on-chip. Front Pharmacol. 2023;14:1114739. doi: 10.3389/fphar.2023.1114739
   PubMed Web of Science ®Google Scholar
• Wolff RK. Perspectives on lung dose and inhaled biomolecules. Toxicol Pathol. 2021;49(2):378–385. doi: 10.1177/0192623320946297
   PubMed Web of Science ®Google Scholar
• Laitano R, Calzetta L, Cavalli F, et al. Delivering monoclonal antibodies via inhalation: a systematic review of clinical trials in asthma and COPD. Expert Opin Drug Deliv. 2023; 1–14. doi: 10.1080/17425247.2023.2228681
   PubMed Web of Science ®Google Scholar
• Humbert M, Busse W, Hanania NA, et al. Omalizumab in asthma: an update on recent developments. J Allergy Clin Immunol Pract. 2014;2(5):525–536. doi: 10.1016/j.jaip.2014.03.010
   PubMed Web of Science ®Google Scholar
• Fahy JV, Cockcroft DW, Boulet LP, et al. Effect of aerosolized anti-IgE (E25) on airway responses to inhaled allergen in asthmatic subjects. Am J Respir Crit Care Med. 1999;160(3):1023–1027. doi: 10.1164/ajrccm.160.3.9810012
   PubMed Web of Science ®Google Scholar
• Hacha J, Tomlinson K, Maertens L, et al. Nebulized anti-IL-13 monoclonal antibody Fab’ fragment reduces allergen-induced asthma. Am J Respir Cell Mol Biol. 2012;47(5):709–717. doi: 10.1165/rcmb.2012-0031OC
   PubMed Web of Science ®Google Scholar
• Lightwood D, Tservistas M, Zehentleitner M, et al. Efficacy of an inhaled IL-13 antibody fragment in a model of chronic asthma. Am J Respir Crit Care Med. 2018;198(5):610–619. doi: 10.1164/rccm.201712-2382OC
   PubMedGoogle Scholar
• Burgess G, Boyce M, Jones M, et al. Randomized study of the safety and pharmacodynamics of inhaled interleukin-13 monoclonal antibody fragment VR942. EBioMedicine. 2018;35:67–75. doi: 10.1016/j.ebiom.2018.07.035
   PubMed Web of Science ®Google Scholar
• Gauvreau GM, Hohlfeld JM, FitzGerald JM, et al. Inhaled anti-TSLP antibody fragment, ecleralimab, blocks responses to allergen in mild asthma. Eur Respir J. 2023;61(3):2201193. doi: 10.1183/13993003.01193-2022
   PubMed Web of Science ®Google Scholar
• Semlali A, Jacques E, Koussih L, et al. Thymic stromal lymphopoietin-induced human asthmatic airway epithelial cell proliferation through an IL-13-dependent pathway. J Allergy Clin Immunol. 2010;125(4):844–850. doi: 10.1016/j.jaci.2010.01.044
   PubMed Web of Science ®Google Scholar